ABBV
stock38ModerateAbbVie Inc.
Health Care
Snapshot
Biopharmaceutical company with immunology (Skyrizi, Rinvoq), aesthetics, and neuroscience franchises. High-margin, high-yield dividend grower.
Long-Term Total Return
Decade-scale view, dividends reinvested, vs. the S&P 500.
Growth of $10,000 invested at the start of the period, total return (price + reinvested dividends). Illustrative.
Risk Profile
Balanced growth with manageable swings.
2–5 Year Outlook
Hypothetical bear / base / bull scenarios — not a prediction.
Hypothetical 5-year scenarios for $10,000 invested today.
| Scenario | Annualized | Total return | $10,000 → |
|---|---|---|---|
| Bull 12%/yr FCF growth, exit 20× FCF | +15.5%/yr | +106% | $20,587 |
| Base 5%/yr FCF growth, exit 17× FCF | +5.5%/yr | +31% | $13,073 |
| Bear 0%/yr FCF growth, exit 12× FCF | -5.0%/yr | -22% | $7,750 |
Projects free cash flow forward and applies an exit valuation multiple (current ≈ 19× FCF). Dividends added at the current yield.
Technical Indicators
Objective price signals — moving averages, RSI, 52-week range — to interpret, not act on.
Illustrative daily prices (last ~9 months) with 50- and 200-day moving averages.
- Below its 200-day moving average — in a longer-term downtrend.
- RSI 41 — neutral (neither overbought nor oversold).
- 24% below its 52-week high.
- MACD is above its signal line (positive momentum).
Technical indicators are objective descriptions of price behavior, not signals to act on. They are computed from illustrative sample prices and say nothing about a company's value. Not investment advice.
Fundamental Trends
Ten-plus years of the figures that drive long-term value.
10-year fundamental trend charts
Track revenue, earnings, free cash flow, ROIC, share count, and dividends over a decade-plus — a Premium research tool.
$9/mo or $84/yr · cancel anytime
Valuation Context
Valuation context
See P/E, P/FCF, and EV/EBITDA against historical and sector medians with Premium.
$9/mo or $84/yr · cancel anytime
Moat Analysis
Patent-protected immunology drugs and a deep pipeline provide pricing power, though patent cliffs require continual replenishment.
Next-gen immunology and neuroscience pipeline aim to offset Humira erosion.
Risk Factors
What could impair the long-term thesis.
- Patent cliffs and biosimilar competition
- High leverage
- Drug-pricing policy
Hypothetical Growth
What a past investment would be worth today.
Hypothetical growth calculator
See what an investment made years ago would be worth today, vs. the S&P 500 — a Premium tool.
$9/mo or $84/yr · cancel anytime
Forward Scenario Modeler
Project a starting investment across multi-decade horizons.
Forward scenario modeler
Model conservative, base, and optimistic returns across 10–40 year horizons with Premium.
$9/mo or $84/yr · cancel anytime
Data as of 2025-12-31. Illustrative sample data for research & education — not live market data, and not a recommendation to buy or sell ABBV.